Top ranking features of the monocytes CD4 T cell gene expression dataset as weighted by the latent factor LF2 which is associated with disease location
| Gene symbol | Latent factor (dataset) | Encoded protein | IBD relevant function | Reference |
| NR4A2 | LF2 (CD4 T cells) | Nuclear receptor subfamily 4 group A member 2 | Imparts protection against IBD by silencing TRAF6/TLR-IL-1R signalling | 72 |
| CSRNP1 | LF2 (CD4 T cells) | Cysteine/serine-rich nuclear protein 1 | – | – |
| SLK1 | LF2 (CD4 T cells) | Serine/threonine-protein kinase SIK1 | Identified as a possible drug target for colitis based on small-molecule screening | 73 |
| FOSB | LF2 (CD4 T cells) | Protein fosB | – | – |
| NR4A1 | LF2 (CD4 T cells) | Nuclear receptor subfamily 4 group A member 1 | Susceptibility loci in a Japanese family with CD; Modulation of inflammation-associated intestinal fibrosis | 74 75 |
| NR4A3 | LF2 (monocytes) | Nuclear receptor subfamily 4 group A member 3 | – | – |
| IL1B | LF2 (monocytes) | Interleukin-1 beta | Increases intestinal tight junction permeability | 76 77 |
| CD69 | LF2 (monocytes) | Early activation antigen CD69 | Modulates mucosal inflammation in patients with IBD | 78 |
| PDE4B | LF2 (monocytes) | cAMP-specific 3',5'-cyclic phosphodiesterase 4B | PDE4 Inhibition confers protection against UC | 79 |
| OSM | LF2 (monocytes) | Oncostatin-M | Drives intestinal inflammation and predicts response to tumour necrosis factor-neutralising therapy; Mediates STAT3-dependent intestinal epithelial restitution; Predicts Crohn’s disease response to Infliximab; Biomarker of poor biochemical response to Infliximab | 80–84 |
.Only the top five features are shown along with their roles in IBD pathogenesis and/or intestinal inflammation.
CD, Crohn’s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.